Inspire Corporate Bond ETF

How Did This Low-Growth Stock Sneak Into IBD Growth Screens?

Investors Business Daily•5d ago

Meta's $1,000 Bull Case: How Muse AI Changes The Valuation Game | IBD

Investors Business Daily•6d ago

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

GuruFocus•10d ago

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

PRNewsWire•10d ago

Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?

Zacks Investment Research•12d ago

Celltrion to Present New Analyses of ZYMFENTRA® (infliximab-dyyb) in Crohn's Disease and Ulcerative Colitis at ACG 2026

GuruFocus•15d ago

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

GuruFocus•15d ago

New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026

GuruFocus•17d ago

Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination Potential

Seeking Alpha•19d ago

AI-Fueled Precision Oncology Firm Guardant Health Is In Focus. Here's Why.

Investors Business Daily•1mo ago

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

GlobeNewsWire•1mo ago

Inspire Corporate Bond Fund (IBD) Receives 5-star Overall Morningstar Rating™ Among 155 Corporate Bond Funds

PRNewsWire•2mo ago

Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?

Zacks Investment Research•2mo ago

Is Inspire Corporate Bond ETF (IBD) a Strong ETF Right Now?

Zacks Investment Research•2mo ago

Beyond The Megacaps: What To Watch In Eli Lilly, Sandisk, SpaceX Earnings | IBD

Investors Business Daily•2mo ago